Press Releases

2017  |  2016  |  2015  |  2014  |  2013


Novel Molecular Assay for Patient Screening Detects S. aureus and Newly Emerging MRSA Strains Available in the United States


BD Board Increases Dividend


Rapid Delivery Program Product Portfolio Expands to Biopharmaceutical Injectable Market


BD Joins National Patient Safety Foundation Corporate Council, Furthers Commitment to Safety


New Collaboration with Industrial Customer Expands NPPD's Renewable Energy Portfolio


Novel Molecular Assay for MRSA Active Surveillance Detects Newly Discovered Strains of Drug Resistant Superbug


BD Diagnostics Presents Integrated Cervical Cancer Testing Solutions at EUROGIN 2013


BD Announces Results for 2013 Fourth Fiscal Quarter and Full Year; Provides Fiscal 2014 Guidance


New Collaboration Aims to Detect More TB Cases in Developing Countries


BD Rx Announces FDA Approval of High Demand Injectable for Pain Management


BD Launches BD Helping Build Healthy CommunitiesSM with Direct Relief and the National Association of Community Health Centers


BD Diagnostics and Sartorius Stedim Biotech Strengthen Cooperation in the Area of Microbiological Diagnostics


BD Announces Live Webcast of Fourth Fiscal Quarter Earnings Conference Call


World Health Organization and BD Announce New Commitment to Address Maternal and Newborn Mortality


Jury Returns Verdict in RTI vs. BD Lawsuit


New Workflow to Provide Scientists with Tools That Enable Single Cell Analysis for Oncology, Immunology and Stem Cell Research


Novel Molecular Assay for Pre Surgical Screening Detects Newly Discovered MRSA Strains


BD to Present at Investor Healthcare Conferences


FDA Approves Third Drug in BD Simplist™ Prefilled Injectable Line of Products


BD ProbeTec™ Trichomonas vaginalis Qx Assay Launches on the BD Viper™ System with XTR™ Technology in the United States


BD Supports the FDA’s Proposal to Reclassify Rapid Influenza Tests


New Syringe Designed to Position More Large Volume Injectable Drugs for Prefill Administration


BD Announces Results for 2013 Third Fiscal Quarter


BD and the College of American Pathologists Announce Strategic Alliance to Support Laboratory Quality and Performance in India and China


BD Board Declares Dividend


BD Appoints Christopher Reidy as Chief Financial Officer


BD Announces Live Webcast Of Third Fiscal Quarter Earnings Conference Call


Menu of Partner Assays for the BD MAX™ System Continues to Expand in Europe


BD’s Latest Pen Needle Innovation Designed to Make Injections Easier for People with Diabetes


New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research


JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes


BD to Present at the Goldman Sachs 34th Annual Global Healthcare Conference


BD and Heart to Heart International Continue Ongoing Collaboration to Help Improve Healthcare in Haiti with Third Volunteer Service Trip


New Prefillable Syringe System Offers Advanced Glass Technology for Biopharmaceutical Injectable Drug Delivery


BD to Present at the Deutsche Bank 38th Annual Health Care Conference


BD Issues 2012 Sustainability Report


BD Board Declares Dividend


BD Announces Results for 2013 Second Fiscal Quarter


BD Diagnostics Advances Commitment to a Fully Integrated Microbiology Solution with New Agreement


FDA Approves Second Drug in BD Simplist™ Prefilled Injectable Line of Products


New Gastrointestinal Tract Infections Assays Launch in Europe


BD Announces FDA 510(k) Clearance and Commercial Launch of BD UltraSafe PLUS™ Passive Needle Guard


New Molecular Assay Provides Healthcare Facilities with a Simple, Efficient Way to Detect Dangerous Superbug


BD Announces Live Webcast of Second Fiscal Quarter Earnings Conference Call


CML HealthCare Inc. to Install North America's First and World's Largest Fully Automated BD Kiestra™ Microbiology Platform


BD Enters Pharmaceutical Industry with New Line of Generic Prefilled Injectable Products


BD Announces Appointment of Dr. Ellen Strahlman as Chief Medical Officer and Senior Vice President, Research & Development


BD Acquires Cato Software Solutions


Independent Study Published in Clinical Infectious Diseases Highlights the Importance of Antimicrobial Removal Systems in Blood Culture to Rapidly and Accurately Aid in the Diagnosis of Sepsis


BD to Present at Investor Healthcare Conferences


BD to Present at Investor Healthcare Conferences


BD Announces Results for 2013 First Fiscal Quarter


Catherine M. Burzik Elected as BD Director


BD Board Declares Dividend


BD Announces Webcast of Annual Meeting of Shareholders


BD PhaSeal™ System Receives Clearance from FDA Under Newly Created ONB Product Code


BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call